ABSTRACT

Sarcoidosis involving Central Nervous system is extremely rare. In nearly 5 to 10 percent of patients with sarcoidosis central nervous system involvement are seen. In contrast Sarcoidosis generally affects lungs in 90% of patient. Neurosarcoidosis affects age groups of 30 to 50 years and females are more affected than males. Neurosarcoidosis generally affects any part of central nervous system and pheripheral nervous system and diagnosis is extremely difficult as there is no definitive test to diagnose it. In treatment part corticosteroids are normally the main line of treatment and around half of patients have significant advantage. For patients who are found non beneficial to corticosteroid treatment, second-line treatment like incorporation of azathioprine, methotrexate, cyclosporine, cyclophosphamide, mycophenolate can be tried. The mix of infliximab and mycophenolate mofetil is under examination too. Here we are going to present a 46 year old male with bilateral lower limb weakness. . This disease can masquerade as many other diseases. Spontaneous improvement or remissions occur in about 60% of patients with neurosarcoidosis. There are no reliable biomarkers identified to monitor disease activity. Since it is rare but important cause of neurological morbidity, and neurological symptoms often herald the diagnosis. A systemic approach is needed for its diagnosis and prompt management. Keywords: Sarcoidosis, Neurosarcoidosis, Granulomatous disease
Publication date: 01/09/2022

https://ijbpas.com/pdf/2022/September/MS_IJBPAS_2022_6421.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.9.6421